相关实验视频

Updated: Jul 5, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

根据EGFR突变状态在非小细胞肺癌中的辐射敏感性差异:临床和体外研究

Hidekazu Tanaka¹, Masako Karita¹, Kazushi Ueda¹

¹Department of Radiation Oncology, Graduate School of Medicine, Yamaguchi University, 1-1-1 Minamikogushi, Ube 755-8505, Yamagcuhi, Japan.

Journal of personalized medicine

|January 22, 2024

概括

具有EGFR突变阳性的非小细胞肺癌 (NSCLC) 显示辐射敏感性增加. 这一发现得到了临床和体外数据的支持,表明放射治疗可能在这些患者中更有效.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
分子生物学分子生物学

背景情况:

目前,对转移性非小细胞肺癌 (NSCLC) 的放射治疗计划不包括驱动基因突变.
表皮生长因子受体 (EGFR) 突变是某些NSCLC病例的关键驱动因素.
了解基于EGFR突变状态的放射性敏感性对于个性化治疗至关重要.

研究的目的:

为了比较非小细胞肺癌 (NSCLC) 具有和没有EGFR驱动基因突变的辐射敏感性.
评估放射治疗在患有和没有EGFR突变的NSCLC患者的临床疗效.
根据EGFR突变状态,研究NSCLC细胞系的体外辐射敏感性.

主要方法:

用Kaplan-Meier分析对42名转移性NSCLC患者进行全脑放射治疗的临床分析,比较EGFR突变阳性 (13名患者) 和EGFR突变阳性 (13名患者) 和EGFR突变阴性组之间的骨控制率.
在体外研究包括殖民地形成试验和DNA双链断裂评估在五个NSCLC细胞系 (2EGFR阴性,3EGFR阳性) 在照射 (0-8 Gy) 后.

主要成果:

与EGFR突变阴性患者相比,EGFR突变阳性NSCLC患者的头骨控制率明显高 (p=0.021).
在体外,EGFR突变阳性NSCLC细胞在2Gy和4Gy辐射后显著减少了殖民地形成 (p=0.002).
EGFR突变阳性细胞在辐射后24小时显著增加了DNA双链断裂 (p<0.001).

结论:

临床和体外发现都表明,具有EGFR突变的非小细胞肺癌 (NSCLC) 对辐射更敏感.
EGFR突变状态是NSCLC放射治疗反应的潜在预测生物标志物.
这表明在NSCLC治疗中根据EGFR突变状态量身定制辐射参数的潜在作用.

关键词:

驱动器突变变异的驱动器皮肤上生长因子受体.非小细胞肺癌的肺癌.辐射治疗疗法辐射治疗疗法辐射敏感性辐射敏感性

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

The Ras Gene

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...